Success Metrics

Clinical Success Rate
100.0%

Based on 8 completed trials

Completion Rate
100%(8/8)
Active Trials
4(33%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
6
50%
Ph phase_3
4
33%
Ph phase_2
2
17%

Phase Distribution

6

Early Stage

2

Mid Stage

4

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
6(50.0%)
Phase 2Efficacy & side effects
2(16.7%)
Phase 3Large-scale testing
4(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

8 of 8 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

12

all time

Status Distribution
Active(4)
Completed(8)

Detailed Status

Completed8
Active, not recruiting3
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
4
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 16 (50.0%)
Phase 22 (16.7%)
Phase 34 (33.3%)

Trials by Status

completed867%
active_not_recruiting325%
recruiting18%

Recent Activity

4 active trials
Showing 5 of 12
active_not_recruitingphase_2

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

NCT06254950
recruitingphase_2

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

NCT06233461
active_not_recruitingphase_3

A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

NCT06550076
completedphase_3

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

NCT06108544
active_not_recruitingphase_3

A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

NCT06323356
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT06254950Phase 2

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Active Not Recruiting
NCT06233461Phase 2

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Recruiting
NCT06550076Phase 3

A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Active Not Recruiting
NCT06108544Phase 3

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

Completed
NCT06323356Phase 3

A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Active Not Recruiting
NCT06088043Phase 3

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

Completed
NCT05976321Phase 1

A Study of TAK-279 in Adults With or Without Liver Damage

Completed
NCT06111547Phase 1

A Study of TAK-279 in Healthy Chinese Adults

Completed
NCT06258265Phase 1

A Study of TAK-279 in Healthy Adults on the Effect on ECG Measurements

Completed
NCT05992155Phase 1

A Study of TAK-279 in Adults With or Without Kidney Problems

Completed
NCT06290050Phase 1

A Study of the Interaction of Other Drugs With TAK-279 in Healthy Adults

Completed
NCT05995249Phase 1

A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12